alligator bioscience

The quick read

What's driving the attention

Alligator Bioscience's stock price has sharply fallen by over 70% following negative developments related to a key drug.

Shares of Alligator Bioscience have plunged more than 70% after the company announced it is halting development of its drug mitazalimab and raising additional capital of 126 million SEK. The drastic stock drop reflects investor concerns regarding the setback in clinical progress. Nonetheless, a recent positive study result from a competitor has sparked some hope for a rally, but overall the company's financial and development challenges have attracted significant market attention.